Livedoid vasculopathy is a rare, chronic, recurrent disease of the cutaneous microcirculation. Its typical clinical manifestation is a triad which consists of livedo racemosa of the skin, episodic painful ulcerations of the distal aspects of the legs and a healing process leaving small porcelain-white scars called atrophie blanche. As an important result of recent research, livedoid vasculopathy has been defined as a coagulation disorder classified as a vasculopathy different from inflammatory vasculitis. This differentiation adds to the current pathophysiologic understanding and supports the therapeutic rationale with respect to the use of new systemic anticoagulants. The prevention of irreversible residual scarring and the improvement of patientsí quality of life are the main goals in treating cutaneous infarction and require early and consequent treatment. This article presents current knowledge on diagnosing this rare disease and offers practical guidance on its therapy.

Download full-text PDF

Source
http://dx.doi.org/10.1111/ddg.12064DOI Listing

Publication Analysis

Top Keywords

livedoid vasculopathy
12
cutaneous infarction
8
vasculopathy current
4
current aspects
4
aspects diagnosis
4
diagnosis treatment
4
treatment cutaneous
4
infarction livedoid
4
vasculopathy rare
4
rare chronic
4

Similar Publications

Janus kinase inhibitors and biologics for treatment of livedoid vasculopathy: a systematic review.

J Dermatolog Treat

December 2025

Department of Dermatology, Xiangya Hospital, Central South University, Changsha, China.

Livedoid vasculopathy (LV) is a chronic microvascular thrombosis disorder with an unclear pathogenesis, potentially involving hypercoagulability and inflammation. This systematic review aims to evaluate the efficacy and safety of Janus kinase (JAK) inhibitors and biologics in the treatment of LV. A comprehensive search was conducted in PubMed, EMBASE, and the Cochrane Library on June 10, 2024, to identify relevant studies evaluating the use of JAK inhibitors and biologics in LV treatment.

View Article and Find Full Text PDF

A 58-year-old female smoker diagnosed with myelodysplastic syndrome (MDS) presented with Raynaud's phenomenon and a "scleroderma-like" pattern on nailfold capillaroscopy. The capillaroscopic abnormalities were observed across all fingers, including those without clinical manifestations of onychomycosis. Over a two-year follow-up, there was no evidence of clinical or serological progression toward a connective tissue disease, particularly systemic sclerosis.

View Article and Find Full Text PDF

Objectives: To assess short-term barnidipine efficacy and tolerability on Systemic Sclerosis (SSc)-Raynaud's phenomenon (RP).

Methods: We retrospectively evaluated patients with SSc starting barnidipine 10 mg/day. Raynaud's Condition Score (RCS) and mean blood pressure (MBP) were assessed at baseline and 6-month follow-up.

View Article and Find Full Text PDF

Livedoid vasculopathy in hemoglobinopathy-associated chronic leg ulcers.

Ann Hematol

December 2024

Division of Hematology, Department of Medicine, UNC Chapel Hill School of Medicine, Chapel Hill, NC, United States of America.

Chronic leg ulceration is a debilitating manifestation of hemoglobinopathies, and best management is uncertain. Livedoid vasculopathy (LV) is a cutaneous non-inflammatory thrombotic vasculopathy treated with anticoagulation that has been identified in hemoglobinopathy-associated chronic leg ulceration. However, most patients with hemoglobinopathy-associated ulcers do not undergo workup for secondary causes, and the prevalence and relevance of LV is unclear.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!